Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

The committee also recommended conditional approval of the drug for the treatment of adult patients with advanced clear cell ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma, according to researchers.

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.